We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+26.78%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$144M
AUM Growth
+$18.8M
(+15%)
Cap. Flow
-$7.43M
Cap. Flow % of AUM
Cap. Flow %
-5.14%
Top 10 Holdings %
Top 10 Hldgs %
90.35%
Holding
19
New
3
Increased
–
Reduced
3
Closed
1
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OBSV
ObsEva SA Ordinary Shares
OBSV
|
+$3.35M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
+$2.26M |
| 3 |
Oncternal Therapeutics, Inc. Common Stock
ONCT
|
+$2.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$8.57M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$6.04M |
| 3 |
Cymabay Therapeutics
CBAY
|
+$387K |
| 4 |
NOVN
Novan, Inc. Common Stock
NOVN
|
+$215K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.13B
| $35.1M | 24.33% |
1,971,907
-472,902
| -19% | -$8.57M |
2016 Q4
3 quarters
|
|
|
SIEN
2
DELISTED
Sientra, Inc.
SIEN
| $33.8M | 23.42% |
219,901
| – | – |
2014 Q4
11 quarters
|
|
|
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $26.1M | 18.09% |
1,041,131
-259,301
| -20% | -$6.04M |
2014 Q4
11 quarters
|
|
|
4
DELISTED
Cymabay Therapeutics
CBAY
| $12.4M | 8.6% |
1,542,722
-57,278
| -4% | -$387K |
2015 Q3
8 quarters
|
|
|
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.31M | 3.67% |
2,080,595
| – | – |
2015 Q3
8 quarters
|
|
6
Protara Therapeutics
TARA
$150M
| $3.94M | 2.72% |
50,447
| – | – |
2014 Q4
11 quarters
|
|
|
CASC
7
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $3.78M | 2.62% |
925,000
| – | – |
2017 Q1
2 quarters
|
|
|
IMDZ
8
DELISTED
Immune Design Corp.
IMDZ
| $3.65M | 2.52% |
352,300
| – | – |
2016 Q2
5 quarters
|
|
|
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $3.48M | 2.41% |
+440,000
| New | +$3.35M |
2017 Q3
0 quarters
|
|
10
Cellectis
CLLS
$134M
| $2.84M | 1.97% |
100,000
| – | – |
2015 Q4
7 quarters
|
|
|
11
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $2.78M | 1.93% |
+2,423
| New | +$2.18M |
2017 Q3
0 quarters
|
|
|
ADAP
12
DELISTED
Adaptimmune Therapeutics
ADAP
| $2.04M | 1.42% |
250,000
| – | – |
2015 Q4
7 quarters
|
|
|
13
Ultragenyx Pharmaceutical
RARE
$1.66B
| $2.03M | 1.4% |
+38,100
| New | +$2.26M |
2017 Q3
0 quarters
|
|
14
DELISTED
Dermira, Inc.
DERM
| $1.89M | 1.31% |
70,000
| – | – |
2015 Q3
8 quarters
|
|
15
Ocugen
OCGN
$296M
| $1.76M | 1.22% |
14,815
| – | – |
2016 Q3
4 quarters
|
|
16
Aurinia Pharmaceuticals
AUPH
$2.17B
| $1.58M | 1.09% |
252,129
| – | – |
2017 Q1
2 quarters
|
|
|
EVAR
17
DELISTED
Lombard Medical, Inc.
EVAR
| $1.53M | 1.06% |
3,473,452
| – | – |
2014 Q3
12 quarters
|
|
|
INNL
18
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $322K | 0.22% |
537,235
| – | – |
2015 Q2
9 quarters
|
|
|
NOVN
19
DELISTED
Novan, Inc. Common Stock
NOVN
| – | – |
-5,337
| Closed | -$215K | – |
|
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q3 2017 Portfolio in Review
As of Q3 2017, Abingworth held 19 positions worth $144M, up 15% from $126M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Abingworth withdrew a net $7.43M in Q3 2017, closing 1 position and reducing 3 holdings. Its most notable exit was Novan, Inc. Common Stock, an estimated $215K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Abingworth opened a new position in ObsEva SA Ordinary Shares worth $3.48M.
- Abingworth's largest Q3 2017 buy was ObsEva SA Ordinary Shares: 440,000 shares worth $3.48M.
- Abingworth's biggest Q3 2017 reduction was CRISPR Therapeutics, cutting an estimated $8.57M.
- Abingworth fully exited Novan, Inc. Common Stock in Q3 2017, selling an estimated $215K.
- Abingworth's ten largest holdings make up 90% of its $144M portfolio in Q3 2017.
- Abingworth opened 3 new positions and closed 1 in Q3 2017.
- Abingworth's portfolio value rose 15% quarter-over-quarter to $144M.
Based on Abingworth's 13F filing for Q3 2017, filed 14 Nov 2017.